Publications by authors named "K Blakely"

Article Synopsis
  • Postpartum depression, a prevalent mood disorder after childbirth, has seen a new treatment option with the FDA's approval of zuranolone (brand name Zurzuvae) in August 2023.!* -
  • Zuranolone functions similarly to benzodiazepines and can be used alone or alongside other antidepressants, offering flexibility in treatment.!* -
  • The medication is taken as a once-daily oral dose for two weeks, allowing women with postpartum depression to manage their symptoms while maintaining their daily activities.!*
View Article and Find Full Text PDF

Post-COVID syndrome, defined as symptoms persisting for more than twelve weeks after the diagnosis of COVID-19, has been recognised as a new clinical entity in the context of SARS-CoV-2 infection. This study was conducted to characterise the burden and predictors for post-COVID-19 syndrome in the local population. It was a community-based web-survey study conducted in Norfolk, East England, UK.

View Article and Find Full Text PDF

Whether certified in acute or primary care, AGNPs are prepared for many practice settings.

View Article and Find Full Text PDF

Canadian emergency departments (EDs) frequently provide care to patients undergoing early pregnancy loss. Unfortunately, in this setting, patients commonly have negative experiences, in part due to lack of appropriate follow-up and education on symptoms that may arise after discharge. In response to this gap, our team created a free, web-based, patient-informed educational platform for women to access accurate information on early pregnancy loss.

View Article and Find Full Text PDF

In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections.

View Article and Find Full Text PDF